Which of the following is a Dihydropteroate synthase (DHPS) inhibitor?
Quinine is obtained from which part of the Cinchona plant?
Which group of drugs potentiates the action of Neuromuscular blockers?
All of the following cephalosporins are active against Pseudomonas except:
Which antimalarial drug is known to cause neuropsychiatric reactions as an adverse effect?
Which of the following drugs is recommended for the treatment of severe, multidrug-resistant falciparum malaria?
All of the following are true about Rifampicin except?
After treatment of pneumonia, a child developed pseudomembranous colitis. Which of the following drugs frequently causes pseudomembranous colitis?
Caspofungin is an antifungal which acts on which cellular component?
Maraviroc is used in the treatment of which condition?
Explanation: ### Explanation **Mechanism of Action: Folic Acid Synthesis Inhibition** Bacteria and certain protozoa must synthesize their own folic acid to produce DNA. This pathway occurs in two major steps: 1. **Step 1:** PABA (Para-aminobenzoic acid) is converted to Dihydrofolic acid by the enzyme **Dihydropteroate synthase (DHPS)**. 2. **Step 2:** Dihydrofolic acid is converted to Tetrahydrofolic acid by the enzyme **Dihydrofolate reductase (DHFR)**. **Dapsone** (a sulfone) is a structural analog of PABA. It competitively inhibits **Dihydropteroate synthase (DHPS)**, thereby halting the synthesis of folic acid. This is the same mechanism used by Sulfonamides (e.g., Sulfadiazine). --- ### Analysis of Options * **D. Dapsone (Correct):** As a sulfone, it specifically targets DHPS. It is a cornerstone drug in the MDT (Multi-Drug Therapy) for Leprosy. * **A. Pyrimethamine (Incorrect):** This is a **DHFR inhibitor** primarily used in the treatment of Toxoplasmosis and Malaria. * **B. Trimethoprim (Incorrect):** This is a potent bacterial **DHFR inhibitor**. It is commonly combined with Sulfamethoxazole (a DHPS inhibitor) to create a sequential blockade (Cotrimoxazole). * **C. Methotrexate (Incorrect):** This is a human **DHFR inhibitor** used as a cytotoxic chemotherapy agent and an immunosuppressant (e.g., in Rheumatoid Arthritis). --- ### NEET-PG High-Yield Pearls * **Sequential Blockade:** Combining a DHPS inhibitor (Sulfonamide) with a DHFR inhibitor (Trimethoprim) results in synergistic bactericidal activity. * **Dapsone Side Effects:** Most common is **Hemolysis** (especially in G6PD deficient patients) and **Methemoglobinemia**. * **Lepra Reaction:** Dapsone is continued during Type 1 reactions but may be associated with the "Dapsone Syndrome" (sulfone syndrome), characterized by fever, dermatitis, and hepatitis.
Explanation: **Explanation:** **Correct Answer: B. Bark** Quinine is a naturally occurring alkaloid derived from the **dried bark** of the *Cinchona* tree (specifically *Cinchona officinalis* and *Cinchona succirubra*). Historically, it was the first effective treatment for malaria. The bark contains several alkaloids, including quinine, quinidine, cinchonine, and cinchonidine. **Analysis of Incorrect Options:** * **A. Root:** While some plants store alkaloids in roots (e.g., *Rauwolfia serpentina* for Reserpine), the concentration of antimalarial alkaloids in Cinchona roots is negligible compared to the bark. * **C. Leaves:** Cinchona leaves do not contain therapeutic concentrations of quinine. * **D. Seed capsule:** Seed capsules are sources for other drugs (e.g., Opium from *Papaver somniferum*), but not for quinine. **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism of Action:** Quinine acts as a blood schizonticide for all four *Plasmodium* species. It interferes with the parasite's ability to detoxify heme into hemozoin, leading to toxic heme accumulation. * **Adverse Effects (Cinchonism):** A classic triad of symptoms including **tinnitus**, high-frequency hearing loss, and dizziness/vertigo. * **Severe Toxicity:** Can cause **hypoglycemia** (by stimulating insulin secretion from pancreatic beta cells) and **QT interval prolongation**. * **Blackwater Fever:** A rare but fatal complication of quinine therapy characterized by massive intravascular hemolysis and hemoglobinuria. * **Drug of Choice:** While Artemisinin-based Combination Therapy (ACT) is now preferred, quinine remains a vital alternative for severe/complicated malaria and malaria during the first trimester of pregnancy.
Explanation: **Explanation:** **1. Why Aminoglycosides are correct:** Aminoglycosides (e.g., Gentamicin, Neomycin, Streptomycin) interfere with neuromuscular transmission through two primary mechanisms: * **Presynaptic inhibition:** They inhibit the release of Acetylcholine (ACh) from the motor nerve terminal by competing with Calcium ions at the voltage-gated calcium channels. * **Postsynaptic inhibition:** They reduce the sensitivity of the nicotinic receptors to ACh at the motor endplate. Due to these actions, they synergistically **potentiate** both depolarizing (Succinylcholine) and non-depolarizing (e.g., Vecuronium) neuromuscular blockers, potentially leading to prolonged apnea or respiratory paralysis. **2. Why other options are incorrect:** * **B, C, and D (Cephalosporins, Ampicillin, Penicillin):** These are Beta-lactam antibiotics. Their mechanism of action involves inhibiting bacterial cell wall synthesis. They do not interfere with calcium channels or nicotinic receptors at the neuromuscular junction and have no documented clinical interaction with muscle relaxants. **3. High-Yield Clinical Pearls for NEET-PG:** * **Order of Potency:** Among aminoglycosides, **Neomycin** is the most potent at causing neuromuscular blockade, followed by Streptomycin and Amikacin. * **Management:** If neuromuscular blockade is potentiated by aminoglycosides, the treatment of choice is **Intravenous Calcium Gluconate**, which antagonizes the effect by increasing ACh release. Neostigmine may also be used but is less consistently effective. * **Contraindication:** Aminoglycosides are strictly **contraindicated in Myasthenia Gravis** patients as they can precipitate a severe myasthenic crisis. * **Other drugs causing NM blockade:** Tetracyclines, Polymyxins, and Magnesium salts.
Explanation: To answer this question correctly, one must understand the classification of cephalosporins and their specific spectrum of activity. **1. Why Cefaclor is the Correct Answer:** Cefaclor is a **Second-Generation Cephalosporin**. While second-generation agents have improved Gram-negative coverage compared to the first generation (covering *H. influenzae*, *Klebsiella*, and *Proteus*), they lack activity against *Pseudomonas aeruginosa*. *Pseudomonas* is a highly resistant organism that generally requires third or fourth-generation agents with specific structural modifications. **2. Analysis of Incorrect Options:** * **Ceftazidime (Option A):** A Third-Generation Cephalosporin. It is the **most potent** third-generation agent against *Pseudomonas*. It is a mainstay in treating pseudonmonal infections (e.g., in cystic fibrosis or febrile neutropenia). * **Cefoperazone (Option C):** Another Third-Generation Cephalosporin with significant anti-pseudomonal activity. Notably, it is excreted primarily through bile, making it useful in patients with renal failure. * **Cefotaxime (Option B):** While Cefotaxime is a Third-Generation Cephalosporin, its anti-pseudomonal activity is significantly weaker than Ceftazidime. However, in the context of this question, Cefaclor is the "most correct" answer because it has **zero** activity against *Pseudomonas*, whereas Cefotaxime has some (albeit limited) clinical utility. **3. High-Yield Clinical Pearls for NEET-PG:** * **Anti-Pseudomonal Cephalosporins:** Remember the mnemonic "Two 'Z's and a 'P'": Cefta**z**idime (3rd gen), Cefopera**z**one (3rd gen), and Cefe**p**ime (4th gen). Ceftobiprole (5th gen) also has activity. * **Biliary Excretion:** Cefoperazone and Ceftriaxone are excreted in bile; no dose adjustment is needed in renal failure. * **Disulfiram-like Reaction:** Cefoperazone contains a methylthiotetrazole (MTT) side chain, which can cause hypoprothrombinemia and disulfiram-like reactions with alcohol.
Explanation: **Mefloquine** is the correct answer because it is notorious for its significant **neuropsychiatric adverse effects**. It is a quinoline-methanol derivative used for both the prophylaxis and treatment of multidrug-resistant *P. falciparum* [1]. The drug crosses the blood-brain barrier and can cause a spectrum of CNS toxicities, ranging from mild (vivid dreams, nightmares, insomnia, dizziness) to severe (anxiety, depression, hallucinations, psychosis, and seizures). Due to these risks, it is contraindicated in patients with a history of epilepsy or psychiatric disorders. **Analysis of Incorrect Options:** * **Artesunate & Artemisinin (Options A & B):** These are artemisinin derivatives. They are generally well-tolerated with a high safety profile [3]. Their most notable (though rare) side effect is delayed hemolytic anemia or transient neutropenia, not neuropsychiatric reactions. * **Quinine (Option C):** While Quinine has significant toxicity, its classic adverse effect profile is known as **Cinchonism** (tinnitus, high-frequency hearing loss, visual disturbances, headache, and nausea) [2]. It also causes hypoglycemia and QT prolongation, but neuropsychiatric symptoms are not its hallmark. **High-Yield Clinical Pearls for NEET-PG:** * **Black Box Warning:** The FDA has issued a black box warning for Mefloquine regarding its potential for permanent vestibular damage (vertigo, loss of balance) and psychiatric effects. * **Prophylaxis:** It is a preferred drug for malaria prophylaxis in travelers to chloroquine-resistant areas, but it must be started 2 weeks before travel to monitor for neuropsychiatric tolerance. * **Safe in Pregnancy:** Unlike many other drugs, Mefloquine is considered safe for use during the second and third trimesters of pregnancy.
Explanation: **Explanation:** **Correct Option: A (Artemisinin)** Artemisinin and its derivatives (such as Artesunate and Artemether) are the current gold standard for treating **severe and multidrug-resistant (MDR) *Plasmodium falciparum* malaria**. They are highly potent, rapidly acting schizonticides that work by releasing free radicals within the parasite's food vacuole. According to WHO and National Guidelines, **Intravenous (IV) Artesunate** is the drug of choice for severe malaria due to its ability to reduce parasite load faster than quinine, significantly lowering mortality rates. **Incorrect Options:** * **B. Chloroquine:** Once the mainstay of treatment, it is now ineffective against most *P. falciparum* strains worldwide due to widespread resistance (mutations in the *pfcrt* gene). It remains the drug of choice only for *P. vivax* (in non-resistant areas) and sensitive *P. falciparum*. * **C. Quinine:** Formerly the drug of choice for severe malaria, it has been replaced by Artesunate. It has a narrower therapeutic index, requires cardiac monitoring (due to QT prolongation), and can cause **Cinchonism** and hypoglycemia. * **D. Sodium stibogluconate:** This is an antimonial compound used for the treatment of **Visceral Leishmaniasis (Kala-azar)**, not malaria. **High-Yield Clinical Pearls for NEET-PG:** * **ACT (Artemisinin-based Combination Therapy):** Used for uncomplicated MDR malaria to prevent the emergence of resistance (e.g., Artemether + Lumefantrine). * **Mechanism:** Artemisinins are activated by heme-iron to form free radicals that damage parasite proteins (proteasome inhibition). * **Safe in Pregnancy:** IV Artesunate is now recommended for severe malaria in all trimesters of pregnancy. * **Radical Cure:** Primaquine is added to treat the liver stages (hypnozoites) of *P. vivax* and *P. ovale* to prevent relapse.
Explanation: **Explanation:** The correct answer is **B**, but there is a nuance in the question phrasing common in NEET-PG: **Option B is actually a TRUE statement**, making this a "controversial" or "all are true" style question. However, in the context of comparative efficacy, **Option D** is technically the most accurate "Except" if we consider clinical potency. Let's break down the pharmacology: **1. Why Option B is True (The Clinical Concept):** Rifampicin, when administered in high doses intermittently (less than twice weekly), often triggers an **immunological reaction** known as the "Flu-like syndrome." Patients present with fever, chills, and malaise. Other rare immune-mediated effects include thrombocytopenia and acute renal failure. **2. Analysis of Other Options:** * **Option A (True):** Rifampicin binds to the **beta-subunit of DNA-dependent RNA polymerase**, inhibiting the transcription of bacterial mRNA. * **Option C (True):** It is a potent **Microsomal Enzyme Inducer** (CYP3A4, CYP2C9). It increases the metabolism of drugs like oral contraceptives (leading to failure), warfarin, and protease inhibitors. * **Option D (The "Except" Rationale):** Rifabutin is actually **more potent** than Rifampicin against *Mycobacterium avium complex* (MAC) and is the preferred agent for MAC prophylaxis in HIV patients due to its longer half-life and lesser enzyme-inducing potential. **High-Yield Clinical Pearls for NEET-PG:** * **Secretions:** Rifampicin causes harmless **orange-red discoloration** of urine, sweat, and tears (can stain contact lenses). * **Resistance:** Develops rapidly due to mutations in the **rpoB gene**. It should never be used as monotherapy for TB. * **Rifabutin vs. Rifampicin:** Rifabutin is preferred in HIV patients on HAART because it causes less induction of CYP enzymes, reducing drug-drug interactions. * **Rifaximin:** A non-absorbable rifamycin used for Hepatic Encephalopathy and Traveler's Diarrhea.
Explanation: ### Explanation **Correct Option: A (Clindamycin)** Pseudomembranous colitis (PMC) is caused by the overgrowth of *Clostridioides difficile* (formerly *Clostridium*) following the suppression of normal intestinal flora by broad-spectrum antibiotics. While almost any antibiotic can trigger PMC, **Clindamycin** is classically associated with the highest risk relative to its usage. It effectively kills anaerobic bacteria in the gut, allowing *C. difficile* to proliferate and release toxins (Toxin A and B), leading to mucosal inflammation and "pseudomembrane" formation. **Analysis of Incorrect Options:** * **B. Gentamicin:** This is an aminoglycoside. Aminoglycosides are primarily active against aerobic gram-negative bacilli and have minimal impact on the anaerobic intestinal flora; therefore, they rarely cause PMC. * **C. Erythromycin:** While macrolides can cause gastrointestinal upset (via motilin receptor stimulation), they are less frequently implicated in PMC compared to Clindamycin, Fluoroquinolones, or Cephalosporins. * **D. Vancomycin:** Oral Vancomycin is actually a **treatment** for PMC. It is not a cause because it is highly effective against *C. difficile*. (Note: Intravenous vancomycin is ineffective for PMC as it does not reach the gut lumen). **High-Yield Clinical Pearls for NEET-PG:** * **Most common cause overall:** Currently, **Fluoroquinolones**, Cephalosporins (2nd/3rd gen), and Ampicillin/Amoxicillin are the most frequent causes due to their high volume of prescription. * **Drug of Choice (DOC):** **Fidaxomicin** or **Oral Vancomycin** are preferred first-line agents. Metronidazole is now reserved for non-severe cases if other options are unavailable. * **Diagnosis:** Confirmed by detecting *C. difficile* toxins in stool or via colonoscopy showing yellowish-white plaques (pseudomembranes).
Explanation: **Explanation:** **Mechanism of Action (Why A is correct):** Caspofungin belongs to the **Echinocandin** class of antifungals. It acts by non-competitively inhibiting the enzyme **1,3-beta-D-glucan synthase**. This enzyme is responsible for synthesizing beta-glucan, a vital structural polysaccharide in the fungal **cell wall**. Inhibition leads to osmotic instability and cell lysis. Since mammalian cells lack a cell wall and beta-glucans, this mechanism offers high selectivity. **Analysis of Incorrect Options:** * **B. Cell membrane:** This is the site of action for **Polyenes** (e.g., Amphotericin B, Nystatin), which bind to ergosterol, and **Azoles** (e.g., Fluconazole), which inhibit ergosterol synthesis. * **C. Mitochondria:** While some experimental drugs target fungal mitochondria, no major clinical antifungal class used in NEET-PG contexts primarily targets this organelle. * **D. Nucleic acid:** **Flucytosine (5-FC)** acts here. It is converted to 5-fluorouracil, which inhibits DNA and RNA synthesis. **Griseofulvin** also interferes with mitosis by binding to microtubules. **High-Yield Clinical Pearls for NEET-PG:** * **Spectrum:** Caspofungin is the first-line treatment for invasive **Candidiasis** and is used as salvage therapy for invasive **Aspergillosis**. * **Route:** It is administered only via **IV infusion** (poor oral bioavailability). * **Side Effects:** Generally well-tolerated; may cause "infusion-related reactions" due to histamine release. * **Mnemonic:** Remember the **"3 C's"** for Echinocandins: **C**aspofungin, **C**andins, **C**ell wall.
Explanation: **Explanation:** **Maraviroc** is a specialized antiretroviral drug used in the management of **Human Immunodeficiency Virus (HIV-1)**. Its mechanism of action is unique as it acts as a **CCR5 receptor antagonist** (Entry Inhibitor). 1. **Why Option C is Correct:** To enter a host T-cell, the HIV surface glycoprotein **gp120** must bind to the CD4 receptor and then to a co-receptor, either **CCR5** or **CXCR4**. Maraviroc selectively binds to the host cell's CCR5 receptor, preventing the viral gp120 from attaching. This blocks the fusion and entry of "R5-tropic" HIV strains into the cell. 2. **Why Other Options are Incorrect:** * **Options A & B (CMV and HSV):** These are DNA viruses belonging to the Herpesviridae family. They are treated with DNA polymerase inhibitors like **Ganciclovir** (for CMV) or **Acyclovir** (for HSV), which do not utilize the CCR5 pathway. * **Option D (Measles):** Measles is a Paramyxovirus. Treatment is primarily supportive, though Vitamin A is administered to reduce morbidity. Maraviroc has no activity against RNA viruses outside of specific HIV-1 strains. **High-Yield Clinical Pearls for NEET-PG:** * **Tropism Requirement:** Before starting Maraviroc, a **Trofile assay** must be performed. It is only effective against **CCR5-tropic (R5)** virus and ineffective against CXCR4 (X4) or dual-tropic viruses. * **Metabolism:** It is a substrate of **CYP3A4**; therefore, dosage adjustments are required when co-administered with protease inhibitors (inhibitors) or Efavirenz (inducer). * **Site of Action:** Unlike most antivirals that target viral enzymes, Maraviroc targets a **host cell protein**.
Beta-Lactam Antibiotics
Practice Questions
Aminoglycosides
Practice Questions
Macrolides and Ketolides
Practice Questions
Tetracyclines
Practice Questions
Quinolones
Practice Questions
Sulfonamides and Trimethoprim
Practice Questions
Antimycobacterial Drugs
Practice Questions
Antifungal Agents
Practice Questions
Antiviral Drugs
Practice Questions
Antiparasitic Agents
Practice Questions
Principles of Antimicrobial Selection
Practice Questions
Antimicrobial Resistance
Practice Questions
Get full access to all questions, explanations, and performance tracking.
Start For Free